EASD 2025 15 - 19 September 2025

Amycretin, a novel, unimolecular glucagon-like peptide-1 and amylin receptor agonist: Results of a phase 1b/2a clinical trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Obesity

Congress oral presentation

GLP-1 RA

Amylin analogue

Amycretin

PHASE 1 (RCT)

PHASE 2 (RCT)